Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares his insights into the AVENuE trial (NCT03617666), a Phase II investigator – initiated study in the UK. Dr Collins discusses the structure of the trial and its potential use in the treatment of classical Hodgkin lymphoma. Dr Collins explains the various stages of the trial, including the use of avelumab, a PD-L1 inhibitor, followed by various chemotherapy treatment options depending on patient response and PET scan results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

свернуть